{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:29:33Z","timestamp":1789759773389,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,5,9]],"date-time":"2009-05-09T00:00:00Z","timestamp":1241827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s00296-009-0940-5","type":"journal-article","created":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T11:13:57Z","timestamp":1241781237000},"page":"213-221","source":"Crossref","is-referenced-by-count":62,"title":["Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis"],"prefix":"10.1007","volume":"30","author":[{"given":"Johann D.","family":"Ringe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,5,9]]},"reference":[{"key":"940_CR1","unstructured":"Dachverband Deutschsprachiger Wissenschaftlicher Gesellschaften f\u00fcr Osteologie (2006) DVO-guideline for prevention, clinical assesssment and treatment of osteoporosis for women after menopause, for men after age 60. http:\/\/www.lutherhaus.de\/osteo\/leitlinien-dvo\/index.php"},{"key":"940_CR2","first-page":"611","volume":"114","author":"J Pfeilschifter","year":"2006","unstructured":"Pfeilschifter J (2006) DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60. Executive summary guidelines. Exp Clin Endocrinol Diabetes 114:611\u2013622","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"940_CR3","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. doi: 10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"940_CR4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1517\/14656566.3.7.835","volume":"3","author":"A DeSantis","year":"2002","unstructured":"DeSantis A, Buchman A (2002) 2002 current and emerging therapies in osteoporosis. Expert Opin Pharmacother 3:835\u2013843. doi: 10.1517\/14656566.3.7.835","journal-title":"Expert Opin Pharmacother"},{"key":"940_CR5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00330-004-2549-0","volume":"15","author":"K Kobayashi","year":"2005","unstructured":"Kobayashi K, Shimoyama K, Nakamura K, Murata K (2005) Percutaneous vertebroplasty immediately relieves pain of osteoporotic vertebral compression fractures and prevents prolonged immobilization of patients. Eur Radiol 15:360\u2013367. doi: 10.1007\/s00330-004-2549-0","journal-title":"Eur Radiol"},{"key":"940_CR6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12019-002-0048-2","volume":"28","author":"DJ Theodorou","year":"2002","unstructured":"Theodorou DJ, Theodorou SJ, Sartoris DJ (2002) Treatment of osteoporosis: current status and recent advances. Compr Ther 28:109\u2013122. doi: 10.1007\/s12019-002-0048-2","journal-title":"Compr Ther"},{"key":"940_CR7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437\u20131443. doi: 10.1056\/NEJM199511303332201","journal-title":"N Engl J Med"},{"key":"940_CR8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541. doi: 10.1016\/S0140-6736(96)07088-2","journal-title":"Lancet"},{"key":"940_CR9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077\u20132082. doi: 10.1001\/jama.280.24.2077","journal-title":"JAMA"},{"key":"940_CR10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352. doi: 10.1001\/jama.282.14.1344","journal-title":"JAMA"},{"key":"940_CR11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391. doi: 10.1007\/s001980050010","journal-title":"Osteoporos Int"},{"key":"940_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00296-005-0004-4","volume":"26","author":"JD Ringe","year":"2006","unstructured":"Ringe JD, Faber H, Farahmand P et al (2006) Efficacy of risedronate in men with primary and secondary osteoporosis. Results of a 1-year study. Rheumatol Int 26:427\u2013431. doi: 10.1007\/s00296-005-0004-4","journal-title":"Rheumatol Int"},{"key":"940_CR13","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut III","year":"2004","unstructured":"Chesnut CHIII, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249. doi: 10.1359\/JBMR.040325","journal-title":"J Bone Miner Res"},{"key":"940_CR14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","volume":"14","author":"JD Ringe","year":"2003","unstructured":"Ringe JD, Dorst A, Faber H et al (2003) Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative trial. Osteoporos Int 14:801\u2013807. doi: 10.1007\/s00198-003-1425-0","journal-title":"Osteoporos Int"},{"key":"940_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340. doi: 10.1056\/NEJM200102013440503","journal-title":"N Engl J Med"},{"key":"940_CR16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. doi: 10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"940_CR17","unstructured":"SEIOMM. http:\/\/www.seiomm.org\/"},{"key":"940_CR18","unstructured":"Nuova Nota 79 relativa all\u2019osteoporosi. http:\/\/www.amiciitalia.org\/nuovo_nota_79.htm"},{"issue":"suppl 1","key":"940_CR19","first-page":"S259","volume":"20","author":"FH Ebetino","year":"2005","unstructured":"Ebetino FH, Barnett BL, Russell RGG (2005) A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonates in clinical use. J Bone Miner Res 20(suppl 1):S259","journal-title":"J Bone Miner Res"},{"key":"940_CR20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","volume":"1117","author":"RG Russell","year":"2007","unstructured":"Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH (2007) Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 1117:209\u2013257. doi: 10.1196\/annals.1402.089","journal-title":"Ann N Y Acad Sci"},{"key":"940_CR21","unstructured":"Actonel\u00ae 5\u00a0mg Filmtabletten Fachinformation"},{"key":"940_CR22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1185\/030079903125003125","volume":"4","author":"C Roux","year":"2004","unstructured":"Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB (2004) Efficacy of risedronate on clinical vertebral fractures within 6 months. Curr Med Res Opin 4:433\u2013439. doi: 10.1185\/030079903125003125","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"940_CR23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"JT Harrington","year":"2004","unstructured":"Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74(2):129\u2013135. doi: 10.1007\/s00223-003-0042-4","journal-title":"Calcif Tissue Int"},{"key":"940_CR24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00198-006-0274-z","volume":"18","author":"SL Silverman","year":"2007","unstructured":"Silverman SL, Watts NB, Delmas PD et al (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25\u201334. doi: 10.1007\/s00198-006-0274-z","journal-title":"Osteoporos Int"},{"key":"940_CR25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1185\/030079905X61875","volume":"21","author":"JA Cramer","year":"2006","unstructured":"Cramer JA, Amonkar MM, Hebborn A, Altman R (2006) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453\u20131460. doi: 10.1185\/030079905X61875","journal-title":"Curr Med Res Opin"},{"key":"940_CR26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","volume":"15","author":"JJ Caro","year":"2004","unstructured":"Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003\u20131008. doi: 10.1007\/s00198-004-1652-z","journal-title":"Osteoporos Int"},{"key":"940_CR27","unstructured":"Sebaldt RJ et al (2004) Impact of non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. Annual European Congress of Rheumatology \u201cEULAR 2004\u201d"},{"issue":"8","key":"940_CR28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases. Mayo Clin Proc 81(8):1013\u20131022","journal-title":"Mayo Clin Proc"},{"key":"940_CR29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"940_CR30","unstructured":"Papaioannou A, Ioannidis G, Grima D, Adachi JD (2008) Quantification and description of gastrointestinal adverse events (GI AES) in patients switched from branded Fosamax\u00ae to generic alendronate. http:\/\/www.iscd.org\/Visitors\/pdfs\/ISCD_abstracts.pdf . Abstract #152"},{"key":"940_CR31","unstructured":"Actonel\u00ae einmal w\u00f6chentlich 35\u00a0mg Filmtabletten Fachinformation Januar 2003"},{"key":"940_CR32","unstructured":"Fosamax\u00ae 10\u00a0mg Fachinformation Fachinformation Februar 2002"},{"key":"940_CR33","unstructured":"Fosamax\u00ae einmal w\u00f6chentlich 70\u00a0mg Tabletten Fachinformation (Zusammenfassung der Merkmale des Arzneimittels, SPC) Mai 2002"},{"key":"940_CR34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928. doi: 10.1016\/j.bone.2005.10.022","journal-title":"Bone"},{"key":"940_CR35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-006-0230-y","volume":"18","author":"D Weycker","year":"2007","unstructured":"Weycker D, Macarios D, Edelsberg J, Oster G (2007) Compliance with osteoporosis drug therapy and risk fracture. Osteoporos Int 18:271\u2013277. doi: 10.1007\/s00198-006-0230-y","journal-title":"Osteoporos Int"},{"key":"940_CR36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","volume":"48","author":"JS McCombs","year":"2004","unstructured":"McCombs JS, Thiebaud P, Laughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271\u2013287. doi: 10.1016\/j.maturitas.2004.02.005","journal-title":"Maturitas"},{"key":"940_CR37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from two US claims databases. Mayo Clin Proc 81:1013\u20131022. doi: 10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"key":"940_CR38","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00198-007-0466-1","volume":"19","author":"FJ Penning-van Beest","year":"2008","unstructured":"Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511\u2013517. doi: 10.1007\/s00198-007-0466-1","journal-title":"Osteoporos Int"},{"issue":"3","key":"940_CR39","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"H Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of nine clinical trials. Mayo Clin Proc 77(3):262\u2013270","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"940_CR40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","volume":"75","author":"DD Mellstr\u00f6m","year":"2004","unstructured":"Mellstr\u00f6m DD, S\u00f6rensen OH, Goemaere S, Roux C, Johnson TD, Chines AA (2004) Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 75(6):462\u2013468","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"940_CR41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.4065\/80.10.1278","volume":"80","author":"S Adami","year":"2005","unstructured":"Adami S, Pavelka K, Cline GA, Hosterman MA, Barton IP, Cohen SB, Bensen WG (2005) Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80(10):1278\u20131285","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"940_CR42","doi-asserted-by":"crossref","first-page":"142","DOI":"10.18553\/jmcp.2004.10.2.142","volume":"10","author":"NB Watts","year":"2004","unstructured":"Watts NB, Worley K, Solis A, Doyle J, Sheer R (2004) Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10(2):142\u2013151","journal-title":"J Manag Care Pharm"},{"key":"940_CR43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","volume":"119","author":"FL Lanza","year":"2000","unstructured":"Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119:631\u2013638. doi: 10.1053\/gast.2000.16517","journal-title":"Gastroenterology"},{"issue":"9","key":"940_CR44","first-page":"1965","volume":"29","author":"AB Thomson","year":"2002","unstructured":"Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA, Risedronate Endoscopy Study Group (2002) 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29(9):1965\u20131974","journal-title":"J Rheumatol"},{"issue":"5","key":"940_CR45","first-page":"347","volume":"13","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Adami S, Miller PD, Olszynski WP, Kendler DL, Silverman SL, Licata AA, Li Z, Gomez-Panzani E (2001) Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) 13(5):347\u2013354","journal-title":"Aging (Milano)"},{"key":"940_CR46","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC deGroen","year":"1996","unstructured":"deGroen PC, Lubbe DF, Hirsch LJ et al (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016\u20131021. doi: 10.1056\/NEJM199610033351403","journal-title":"N Engl J Med"},{"key":"940_CR47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1185\/030079908X280725","volume":"24","author":"RJ Dansereau","year":"2008","unstructured":"Dansereau RJ, Crail DJ, Perkins AC (2008) In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70\u00a0mg) and in vivo implications. Curr Med Res Opin 24:1137\u20131145. doi: 10.1185\/030079908X280725","journal-title":"Curr Med Res Opin"},{"key":"940_CR48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.clinthera.2008.04.018","volume":"30","author":"AC Perkins","year":"2008","unstructured":"Perkins AC, Blackshaw PE, Hay PD, Lawes SC, Atherton CT, Dansereau RJ, Wagner LK, Schnell DJ (2008) Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single blind, si-period crossover study in healthy female subjects. Clin Ther 30:834\u2013844. doi: 10.1016\/j.clinthera.2008.04.018","journal-title":"Clin Ther"},{"key":"940_CR49","first-page":"253","volume":"5","author":"S Epstein","year":"2005","unstructured":"Epstein S, Geusens P, Fisher JE et al (2005) Disintegration and esophageal irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Appl Res 5:253\u2013264","journal-title":"J Appl Res"},{"key":"940_CR50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1185\/030079903125002577","volume":"19","author":"S Epstein","year":"2003","unstructured":"Epstein S, Cryer B, Gagi S et al (2003) Disintegration\/dissolution profiles of copies of fosamax (alendronate). Curr Med Res Opin 19:781\u2013789. doi: 10.1185\/030079903125002577","journal-title":"Curr Med Res Opin"},{"key":"940_CR51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18:75\u201385. doi: 10.1016\/8756-3282(95)00445-9","journal-title":"Bone"},{"key":"940_CR52","unstructured":"Fleisch H (2000) Bisphosphonates in bone disease: from the laboratory to the patient. Academic Press, New York. ISBN: 0-12-260370-2. 2.4 Pharmacokinetics, pp 56\u201362"},{"key":"940_CR53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(02)07451-2","volume":"359","author":"DA Grimes","year":"2002","unstructured":"Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359:248\u2013252. doi: 10.1016\/S0140-6736(02)07451-2","journal-title":"Lancet"},{"key":"940_CR54","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"N Black","year":"1996","unstructured":"Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215\u20131218","journal-title":"BMJ"},{"key":"940_CR55","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","volume":"11","author":"R Dowd","year":"2000","unstructured":"Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533\u2013536. doi: 10.1007\/s001980070097","journal-title":"Osteoporos Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-0940-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-0940-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-0940-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T03:12:52Z","timestamp":1633403572000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-0940-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,9]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-0940-5","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,9]]}}}